Company Vision: Harness the power of digital printing technology and extensive contact lens manufacturing experience to commercialize a drug-eluting, cost-effective, and comfort-enhancing contact lens to help treat ocular diseases for millions of affected patients world-wide. Leo Lens Pharma has developed a proprietary technology and ink that allows for the sustained release of ocular drugs via contact lenses. The use of cutting-edge digital printing technology, with 3D printing concepts, allows Leo Lens to not only digitally print ‘drug-loaded ink’ on the surface of existing FDA-approved contact lenses, but to also modulate the drug release rate by building appropriate 3D drug reservoirs and barrier layers. This novel approach to printing on contact lenses will create a new application for contact lenses – as drug delivery devices for many ocular diseases like glaucoma, allergy, infection, and dry eye. Glaucoma alone will affect 79.6 million people worldwide in 2020 and poses a serious public health challenge with an aging population, as it results in vision loss and is the second leading cause of irreversible blindness if left untreated. Traditionally, glaucoma is treated with topical medications, such as eye drops. However, topical treatments face problems such as low bioavailability, increased side effects, and poor patient compliance. Alternatively, invasive treatments are available, but they are cost-prohibitive and require continuous follow-up for most patients. Leo Lens has a solution that allows for increased patient compliance with minimal cost difference compared to existing topical treatments Leo Lens Pharma is focused on commercializing a technology for various applications of digital printing on contact lenses for enhancing the health, vision, and beauty of eyes. Currently, the team has developed a global patent portfolio of 25+ patents.